Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Mol Med Rep. 2013 Aug;8(2):456-62. doi: 10.3892/mmr.2013.1517. Epub 2013 Jun 11.
Recent advances in the treatment of non-small cell lung cancer (NSCLC) with new agents require accurate histological subtyping at diagnosis to avoid the higher risk of an adverse response and to obtain the maximum therapeutic response. However, interobserver variability, tumor heterogeneity and the degree of differentiation may affect the decision concerning a pathological diagnosis of NSCLC. Therefore, the aim of this study was to identify specific microRNAs (miRNAs) as standardized biomarkers with high sensitivity and specificity in order to distinguish between squamous cell carcinoma (SCC) and adenocarcinoma (AC). Quantitative polymerase chain reaction (qPCR)‑based miRNA array analysis was performed to identify microRNAs differentially expressed between SCC and AC using 86 resected NSCLC samples in addition to adjacent normal tissues. The results were confirmed by independent qRT-PCR assays with the same test samples and 88 additional validation samples, and from this we evaluated the usefulness of the identified miRNAs as biomarkers to distinguish between SCC and AC. Three miRNAs (hsa-miR-196b, hsa-miR-205 and hsa-miR-375) were identified. Discriminant analysis combining the three miRNAs appeared to distinguish SCC from AC accurately in the test and validation samples, demonstrating a sensitivity and specificity of 76 and 80%, and 85 and 83%, respectively. hsa-miR-196b, hsa-miR-205 and hsa-miR-375 were identified as biomarkers capable of distinguishing between lung SCC and lung AC. These newly identified miRNAs may prove to be highly valuable molecular markers for the classification of NSCLC histological subtypes and may contribute to the pathogenesis of each subtype of NSCLC.
最近在使用新药物治疗非小细胞肺癌 (NSCLC) 方面取得了进展,这要求在诊断时进行准确的组织学亚型分类,以避免不良反应风险增加,并获得最佳的治疗反应。然而,观察者间的变异性、肿瘤异质性和分化程度可能会影响 NSCLC 的病理诊断决策。因此,本研究旨在确定特定的 microRNAs(miRNAs)作为具有高灵敏度和特异性的标准化生物标志物,以区分鳞状细胞癌 (SCC) 和腺癌 (AC)。使用 86 个切除的 NSCLC 样本和相邻正常组织进行了基于定量聚合酶链反应 (qPCR) 的 miRNA 阵列分析,以确定 SCC 和 AC 之间表达差异的 microRNAs。通过使用相同的测试样本和 88 个额外的验证样本进行独立的 qRT-PCR 检测,对结果进行了验证,并从这些样本中评估了鉴定的 microRNAs 作为区分 SCC 和 AC 的生物标志物的有用性。鉴定出 3 个 miRNAs(hsa-miR-196b、hsa-miR-205 和 hsa-miR-375)。结合这 3 个 miRNA 的判别分析似乎可以在测试和验证样本中准确地区分 SCC 和 AC,在测试和验证样本中的灵敏度和特异性分别为 76%和 80%,85%和 83%。hsa-miR-196b、hsa-miR-205 和 hsa-miR-375 被鉴定为能够区分肺 SCC 和肺 AC 的生物标志物。这些新鉴定的 miRNAs 可能成为 NSCLC 组织学亚型分类的非常有价值的分子标志物,并有助于每种 NSCLC 亚型的发病机制。